Free Trial

Vertex Pharmaceuticals (VRTX) Earnings Date, Estimates & Call Transcripts

Vertex Pharmaceuticals logo
$366.54 -9.09 (-2.42%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$366.75 +0.21 (+0.06%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Earnings Summary

Vertex Pharmaceuticals announced Q2 2025 earnings on August 4, 2025, reporting an EPS of $4.52, which topped the consensus estimate of $4.24 by $0.28. Quarterly revenue rose 11.3% year-over-year to $2.94 billion, above analysts' expectations of $2.90 billion. With a trailing EPS of $13.99 and a P/E Ratio of 26.20, Vertex Pharmaceuticals' earnings are expected to grow 12.03% next year, from $15.63 to $17.51 per share.

Latest Q2
Earnings Date
Aug. 4Confirmed
Consensus EPS
(Aug. 4)
$4.24
Actual EPS
(Aug. 4)
$4.52 Beat By $0.28
Actual Revenue
(Aug. 4)
$2.94B

Q2 2025 Earnings Resources

Get Vertex Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vertex Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

VRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vertex Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue Guidance
Q1 20252$3.50$3.61$3.56
Q2 20253$3.59$4.00$3.76
Q3 20253$3.90$4.29$4.11
Q4 20253$4.01$4.87$4.42
FY 2025 11 $15.00 $16.77 $15.84
Q1 20261$3.85$3.85$3.85
Q2 20261$3.95$3.95$3.95
Q3 20261$4.13$4.13$4.13
Q4 20261$4.59$4.59$4.59
FY 2026 4 $16.52 $16.52 $16.52
Q1 20271$4.27$4.27$4.27

Vertex Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025$4.24$4.52+$0.28$3.99$2.90B$2.94B
5/5/2025Q1 2025$4.29$4.06 -$0.23$2.49$2.85B$2.77B
2/10/2025Q4 2024$3.99$3.54 -$0.45$3.50$2.78B-
11/4/2024Q3 2024$3.61$4.38+$0.77$4.07$2.69B$2.77B
8/1/2024Q2 2024-$12.54-$12.83 -$0.29-$12.62$2.66B$2.65B
5/6/2024Q1 2024$3.66$4.76+$1.10$4.37$2.58B$2.69B
2/5/2024Q4 2023$3.85$4.20+$0.35$3.43$2.50B$2.52B
11/6/2023Q3 2023$3.53$4.08+$0.55$3.37$2.50B$2.48B

Vertex Pharmaceuticals Earnings - Frequently Asked Questions

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earning data on Monday, August 4, 2025. Learn more on VRTX's earnings history.

Vertex Pharmaceuticals updated its FY 2025 earnings guidance on Monday, August, 4th. The company issued revenue guidance of $11.9 billion-$12.0 billion, compared to the consensus revenue estimate of $11.9 billion.

In the previous quarter, Vertex Pharmaceuticals (NASDAQ:VRTX) reported $4.52 earnings per share (EPS) to beat the analysts' consensus estimate of $4.24 by $0.28. Learn more on analysts' earnings estimate vs. VRTX's actual earnings.

The conference call for Vertex Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Vertex Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Vertex Pharmaceuticals (NASDAQ:VRTX) has a recorded annual revenue of $11.02 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a recorded net income of -$535.60 million. VRTX has generated $13.99 earnings per share over the last four quarters.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a trailing price-to-earnings ratio of 26.20 and a forward price-to-earnings ratio of 23.45.

Vertex Pharmaceuticals' earnings are expected to grow from $15.63 per share to $17.51 per share in the next year, which is a 12.03% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:VRTX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners